Termination of Systemic Immunity in the Presence of Intraocular Tumors: Influence of Ocular Immune Privilege on Tumor Vaccines

REFERENCES

• Taylor A. A review of the influence of aqueous humor on immunity. Ocul Immunol Inflamm. 2003; 11: 231–241, [CSA]
   PubMed Web of Science ®Google Scholar
• Green D R, Ferguson T A. The role of Fas ligand in immune privilege. Nature Rev Mol Cell Biol. 2001; 2: 917–924, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Streilein J W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003; 3: 879–889, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kaplan H J, Streilein J W. Immune response to immunization via the anterior chamber of the eye. I. Lymphocyte-induced immune deviation. J Immunol. 1977; 118: 809–814, [CSA]
   PubMed Web of Science ®Google Scholar
• Wilbanks G A, Streilein J W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). I. Evidence that an antigen specific ACAID-inducing cell associated signal exists in the peripheral blood. J Immunol. 1991; 146: 2610–2617, [CSA]
   PubMed Web of Science ®Google Scholar
• Wilbanks G A, Mammolenti M M, Streilein J W. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood borne signals that induce ACAID. J Immunol. 1991; 146: 3018–3024, [CSA]
   PubMed Web of Science ®Google Scholar
• Ksander B R, Streilein J W. Failure of precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J Immunol. 1990; 145: 2057–2063, [CSA]
   PubMed Web of Science ®Google Scholar
• Ksander B R, Bando Y, Acevedo J, Streilein J W. Infiltration and accumulation of precursor cytotoxic T cells increase with time in progressively growing ocular tumors. Cancer Res. 1991; 51: 3153–3158, [CSA]
   PubMedGoogle Scholar
• Ksander B R, Mammolenti M M, Streilein J W. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function. Transplantation. 1991; 52: 128–133, [CSA]
   PubMedGoogle Scholar
• Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol. 2000; 12: 571–575, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Antonia S J. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther. 1999; 1: 50–56, [CSA]
   PubMedGoogle Scholar
• Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol. 1995; 13: 251–276, [CSA]
   PubMed Web of Science ®Google Scholar
• Seder R A, Gazzinelli R, Sher A, Paul W E. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA. 1993; 90: 10188–10192, [CSA]
   PubMed Web of Science ®Google Scholar
• Vesosky B, Hurwitz A A. Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother. 2003; 52: 663–669, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen P W, Geer D C, Podack E R, Ksander B R. Tumor cells transfected with B7-1 and interleukin12 cDNA induce protective immunity. Ann NY Acad Sci. 1996; 795: 325–327, [CSA]
   PubMedGoogle Scholar
• Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med. 1983; 157: 1040–1052, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maryanski J L, Van Snick J, Cerottini J C, Boon T. Immunologic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol. 1982; 12: 401–406, [CSA]
   PubMedGoogle Scholar
• Boon T, Van Snick J, Van Pel A, et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med. 1994; 152: 1184–119, [CSA], [CROSSREF]
   Google Scholar
• Velders M P, Markiewicz M A, Eiben G L, Kast W M. CD4+ T cells matter in tumor immunity. Int Rev Immunol. 2003; 22: 113–140, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhou G, Lu Z, McCadden J D, et al. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med. 2004; 200: 1581–1592, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ahmad M, Rees R C, Ali S A. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004; 53: 844–854, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Portielje J E, Gratama J W, van Ojik H H, et al. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 2003; 52: 133–144, [CSA]
   PubMed Web of Science ®Google Scholar
• Hull G W, Mccurdy M A, Nasu Y, et al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res. 2000; 6: 4101–4109, [CSA]
   PubMed Web of Science ®Google Scholar
• Pulaski B A, Clements V K, Pipeling M R, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors an d monokine induced by interferon gamma. Cancer Immunol Immunother. 2000; 49: 34–45, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Carroll M W, Overwijk W W, Surman D R, Tsung K, Moss B, Restifo N P. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst. 1998; 90: 1881–1887, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Zitvogel L, Robbins P D, Storkus W J, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol. 1996; 26: 1335–1341, [CSA]
   PubMed Web of Science ®Google Scholar
• Niederkorn J Y, Streilein J W. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J Immunol. 1983; 131: 2587–2594, [CSA]
   PubMedGoogle Scholar
• Ksander B R, Streilein J W. Immune privilege to MHC disparate tumor grafts in the anterior chamber of the eye I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response. Transplantation. 1989; 47: 661–667, [CSA]
   PubMedGoogle Scholar
• Niederkorn J Y, Streilein J W, Kripke M L. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation. J Natl Cancer Inst. 1983; 71: 193–199, [CSA]
   PubMedGoogle Scholar
• Ma D, Alizadeh H, Comerford S A, et al. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994; 13: 361–369, [CSA]
   PubMed Web of Science ®Google Scholar
• Ma D, Comerford S, Bellingham D, et al. Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye. Transplantation. 1994; 57: 718–725, [CSA]
   PubMedGoogle Scholar
• Schurmans L HRM, den Boer A Th, Diehl L, et al. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 1999; 59: 5250–5254, [CSA]
   PubMed Web of Science ®Google Scholar
• Borbulevych O Y, Baxter T K, Yu Z, et al. Increased immunogenicity of an anchor-modified tumor-associated antigen is due ot the enhanced stability of the peptide / MHC complex: implications for vaccine design. J Immunol. 2005; 174: 4812–4820, [CSA]
   PubMed Web of Science ®Google Scholar
• Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem. 2005; 12: 629–639, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Romero P, Valmori D, Pittet M J, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002; 188: 81–96, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dunn G P, Old L J, Schreiber R D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137–148, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dunn G P, Old L J, Schreiber R D. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22: 329–360, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dunn G P, Bruce A T, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991–998, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kosiewicz M M, Okamoto S, Miki S, et al. Imposing deviant immunity on the presensitized state. J Immunol. 1994; 153: 2962–2973, [CSA]
   PubMed Web of Science ®Google Scholar
• Streilein J W, Niederkorn J Y, Shadduck J A. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J Exp Med. 1980; 152: 1121–1125, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar